NEW YORK (GenomeWeb News) — Agilent Technologies will manufacture the small-interfering RNA component of an RNAi therapeutic being developed by Intradigm, the firms said last week.
Agilent will supply the siRNA material for use in Intradigm’s preclinical oncology candidate, ICS-283. According to the firms, ICS-283 is the only RNAi therapeutic in development against a clinically validated oncology target, in this case vascular endothelial growth factor.
Intradigm has developed the RNAi Nanoplex delivery system for administering RNAi therapeutics.
Financial terms of the alliance were not disclosed.